What's Hot
View all perspectives
Aurelie Najm AurelieRheumo
3 years 6 months ago
Serious infections and BioDMARDs: what is the confounding factor?
BSRBR-RA: 33,916 RA treated w/ BioDMARDs with 62,532 years of follow-up, 2036 SI. HR of SI no longer different among BioDMARDs when adjusted for the line of therapy! #OP0241@Rheumnow #EULAR2021 https://t.co/UG9WrXP7RD
Aurelie Najm AurelieRheumo
3 years 6 months ago
COVID-19 Global Rheum Alliance Registry: prediction of ARDS by machine learning algorithm in a model using 42 variables including:
demographics, rheumatic D, meds and comorb with Sens 0.81, Spe 0.49, AUC 075. Interesting model for close monitoring #OP0288 @Rheumnow #EULAR2021 https://t.co/9YY0jzDx59
Aurelie Najm AurelieRheumo
3 years 6 months ago
PreCARA: analysis of cord blood levels of TNFi in RA pregnancy:
-CTZ n=68 measured in 5.9% and low concentrations
-ETA n=28 not detected
-ADA n=24 in 50% low C
-INF n=13 in 61.5% low C
for both even in patients who discontinued at GA 20 weeks.
@RheumNow #EULAR2021 #POS0202 https://t.co/osBrmbepkb
Aurelie Najm AurelieRheumo
3 years 6 months ago
D2T RA is definitely a complex disease interlinked w/ multimorbidity
@ElenaNikiUK reminds us of the importance of:
1) Detecting comorbidities
2) Adress multimorbidity
to 3) Provide patient-centred care tailored to their specific needs #EULAR2021 @RheumNow https://t.co/ebyYDqnQ1k
Aurelie Najm AurelieRheumo
3 years 6 months ago
RA: total comorbidity count ≤1 (vs ≥ 2) predicts LDA/Rem @6 months ttmt [OR 4.1 p=0.005], while RDCI=0 (vs. ≥ 1) predicts HAQ improvement ≥0.25 [OR 2.6 p=0.046] Basal predictors of D2TRA: RDCI≥ 1(vs. 0) [OR 3.3 -p = 0.024], female sex and age
#OP02999 @Rheumnow #EULAR2021 https://t.co/wc16oCKcix
Dr. Rachel Tate uptoTate
3 years 6 months ago
#EULAR2021 key note speaker, Mark Pollock, is a model of resiliency after blindness and later, a spinal cord injury. "Sometimes we have the luxury of choosing our challenges and sometimes the challenges choose us." @RheumNow
Dr. Rachel Tate uptoTate
3 years 6 months ago
Poster from Cohen et al #POS0220 at #EULAR2021 No new safety signals in UPA treated RA patients in 4.5 years of SELECT clinical trial data. @RheumNow https://t.co/Q48ZaUee8q
Dr. Rachel Tate uptoTate
3 years 6 months ago
ASTERA phase 3 analysis: NTK leads to decline of disease activity in AS pts irrespectively of sacroiliitis on MRI. Abstract #OP0142 #EULAR2021 @RheumNow https://t.co/51f18728ZB https://t.co/qZcsMlKqbW
Dr. Rachel Tate uptoTate
3 years 6 months ago
Real world data from German AQUILA: SEC improved PsA dz activity in M & F pts. Female pts had higher dz burden prior to tx. #EULAR2021 Poster #POS0123 @RheumNow https://t.co/cNIN6yqN0j https://t.co/nPZLDztxQP
Dr. Rachel Tate uptoTate
3 years 6 months ago
Phase 2 Deucravacitinib, oral, selective TYK2i results: Analyses confirmed the efficacy of deucravacitinib vs PBO across TNFi & body weight subgroups. Safety profile similar to that found in PsO trials. Abstract #OP0227 #EULAR2021 @RheumNow https://t.co/BBvn5MaXPp https://t.co/jWFhpmkuC5
Dr. Rachel Tate uptoTate
3 years 6 months ago
KEEPsAKE 2 results: RZB showed greater improvements in signs & symptoms of PsA vs PBO, met all primary/secondary endpoints, & was well tolerated in Bio-IR or csDMARD-IR pts. Safety profile consistent w/ PsO trials. Abstract #OP0228 #EULAR2021 @RheumNow https://t.co/jsF2JVTupg https://t.co/oiZWZ7Pkf2
Dr. Rachel Tate uptoTate
3 years 6 months ago
GRAPPA 2021 treatment update highlights!
▶️Domain-specific tx choices
▶️Uveitis & IBD added
▶️ IL17i, IL23i, & JAKi strongly recommended in multiple domains
▶️PDE4i recs for dactylitis, enthesitis, & nail PsO
▶️Against IL6i
#OP0229 #EULAR2021 @RheumNow https://t.co/5KFQu7myPO https://t.co/R9YSZBwFDh
Dr. Rachel Tate uptoTate
3 years 6 months ago
COSMOS study results: GUS 100 mg Q8W showed ⬆️ACR20 vs PBO at W24; results of prespecified sensitivity and subgroup analyses were consistent. Safety profile consistent with PsO & biologic-naïve PsA pts. Abstract #OP0230 #EULAR2021 @RheumNow https://t.co/CFN1MHB9yv https://t.co/BOZqyqaHPe
Dr. Rachel Tate uptoTate
3 years 6 months ago
The Association of Psoriatic Arthritis abstract #OP0219 showed no clinically relevant ^ in mortality rate observed in PsA patients between 2003-2018. Mortality trends were similar to those in the general population. #EULAR2021 @RheumNow https://t.co/c45XBLvWrz
Dr. Rachel Tate uptoTate
3 years 6 months ago
Data from 5 Nordic registries cohorts in #OP0222: incidence of ILD is 🔽in bDMARD treated PsA vs. RA pts, irrespective of co-medication with MTX. I wonder about evolving dx/seropositivity in pts w/ respect to ILD. #EULAR2021 @RheumNow https://t.co/0qFuXcPhmO https://t.co/gTUUtw80Lv
Poster Hall